Charu Aggarwal, MD
Hematology & Oncology · Philadelphia, PANPI 1114181740
Payments from drug & device makers
Across 468 payments — averaging $14,938 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$3.2M
- AstraZeneca$1.9M
- Daiichi Sankyo Inc.$626K
- Array Biopharma Inc$409K
- Macrogenics, Inc.$325K
- Astrazeneca UK Limited$212K
- plus $307K from 35 others
Across 3 payments — averaging $3491.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$9K
- Pfizer$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 85 | $3,191,318 |
| AstraZeneca | 142 | $1,921,230 |
| Daiichi Sankyo Inc. | 31 | $625,943 |
| Array Biopharma Inc | 3 | $408,500 |
| Macrogenics, Inc. | 6 | $325,105 |
| Astrazeneca UK Limited | 78 | $211,636 |
| Incyte Corporation | 18 | $112,535 |
| Genmab A/s | 7 | $40,643 |
| Sanofi | 7 | $27,446 |
| Pfizer | 9 | $15,437 |
| Eli Lilly | 16 | $11,507 |
| E.r. Squibb & Sons, L.L.C. | 1 | $9,750 |
| Bristol Myers Squibb | 8 | $8,897 |
| Genentech USA, Inc. | 3 | $8,310 |
| AbbVie | 4 | $6,999 |
| Lilly USA, LLC | 7 | $6,849 |
| Janssen Scientific Affairs, LLC | 5 | $6,210 |
| Johnson & Johnson | 4 | $6,165 |
| Blueprint Medicines Corporation | 3 | $5,636 |
| Immunocore Limited | 1 | $4,800 |
| Boehringer Ingelheim | 3 | $4,125 |
| Shionogi Inc | 1 | $4,000 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $3,828 |
| Jazz Pharmaceuticals Inc. | 1 | $3,720 |
| Novocure Inc. | 2 | $3,025 |
| Foundation Medicine, Inc. | 2 | $2,750 |
| Organon | 1 | $2,500 |
| Regeneron Healthcare Solutions, Inc. | 1 | $2,247 |
| Life Technologies Corporation | 1 | $2,000 |
| Eisai Inc. | 1 | $1,875 |
| Gilead | 3 | $1,590 |
| Beigene, Ltd. | 1 | $1,430 |
| Amgen | 1 | $1,298 |
| Mirati Therapeutics, Inc. | 1 | $750 |
| Novartis | 2 | $613 |
| Seagen Inc. | 1 | $152 |
| Genmab U.S., Inc. | 2 | $148 |
| Tempus AI, Inc | 1 | $124 |
| Caris MPI, Inc. | 1 | $31 |
| Astrazeneca AB | 1 | $18 |
| Bayer | 1 | $14 |
How this compares
$6,991,154 in reported general payments places this provider in the 95th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Philadelphia
- Stephen BagleyPhiladelphia$13.1M
- Stephen SchusterPhiladelphia$9.5M
- Pooja GhataliaPhiladelphia$8.3M
- Corey LangerPhiladelphia$7.7M
- Alfred GarfallPhiladelphia$7.6M
- Marcela MausPhiladelphia$4.4M
- Catherine LaiPhiladelphia$3.8M
- James StevensonPhiladelphia$3.4M
- Tara MitchellPhiladelphia$3.2M
- Henry FungPhiladelphia$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.